The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Following the demerger of ITC Hotels from ITC Ltd, Nuvama expects an outflow of approximately $180 million due to the ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...

Auto companies are estimated to report a YoY growth of 9% in Revenue, 9% in EBITDA, and 6% in PAT for Q3FY25. The raw ...

Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

The Indian economy has seen a sharp slowdown, with real GDP growth falling from 8.2 per cent in FY24 to 6 per cent in the first half of FY25. The report highlights a convergence in real and nominal ...

Mixed Q3FY25 outlook for retail industry with jewellery and value retail leading growth, footwear and apparel showing ...

Media companies expected to report muted Q3FY25 results with some segments showing growth, but overall performance remains ...